Citigroup Issues Pessimistic Forecast for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its target price lowered by equities researchers at Citigroup from $117.00 to $110.00 in a research note issued on Tuesday, Marketbeat reports. The brokerage presently has a “buy” rating on the medical technology company’s stock. Citigroup’s price target points to a potential upside of 24.09% from the company’s current price.

A number of other research firms have also recently issued reports on MDT. Needham & Company LLC reiterated a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research report on Thursday, March 26th. Argus lowered their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Monday. UBS Group reiterated a “neutral” rating and set a $104.00 price objective on shares of Medtronic in a research report on Wednesday, February 4th. Robert W. Baird lowered their price objective on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Finally, Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.10.

Medtronic Price Performance

Shares of NYSE:MDT opened at $88.65 on Tuesday. The firm has a 50 day moving average of $93.66 and a 200-day moving average of $96.07. The stock has a market capitalization of $113.81 billion, a PE ratio of 24.69, a PEG ratio of 2.24 and a beta of 0.75. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the previous year, the company earned $1.38 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDT. Artisan Partners Limited Partnership increased its holdings in Medtronic by 2.6% during the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after buying an additional 31,314 shares during the last quarter. SageView Advisory Group LLC increased its holdings in Medtronic by 164.8% during the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the last quarter. CSM Advisors LLC increased its holdings in Medtronic by 13.2% during the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after buying an additional 33,167 shares during the last quarter. UMB Bank n.a. increased its holdings in Medtronic by 65.8% during the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares during the last quarter. Finally, Applied Finance Capital Management LLC purchased a new stake in Medtronic during the third quarter worth about $1,308,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands robotic/surgical addressable market — Medtronic received U.S. FDA clearance for its AI-enabled Stealth AXiS system for cranial and ENT procedures, extending the platform beyond spine and broadening opportunities in computer-assisted and robotic surgery. This is a clear product-side growth catalyst for surgical robotics and navigation adoption. Assessing Medtronic Valuation After Stealth AXiS FDA Clearance
• Positive Sentiment: Market tailwinds in core device markets — industry reports highlight multi-year growth in anesthesia/respiratory and lung-cancer surgery markets, with Medtronic named among leading vendors; these secular trends support steady revenue opportunities for MDT’s device franchises. Anesthesia & Respiratory Market Report Lung Cancer Surgery Market
• Neutral Sentiment: Investor note and price action coverage — market write-ups (e.g., Zacks) point to MDT’s intraday move and recent momentum; useful for short-term sentiment tracking but largely descriptive. Zacks: What Investors Need to Know
• Neutral Sentiment: Mixed analyst adjustments — several firms trimmed price targets (Evercore, Citi, others) but mostly kept positive/neutral ratings (buy/outperform/hold). That leaves medium-term upside in some models but increases short-term uncertainty. Evercore PT Adjustment Citi PT Adjustment
• Negative Sentiment: Stifel trims target citing MiniMed IPO impacts — Stifel cut its price target to $95 and flagged transaction-related effects from the recent MiniMed IPO as a reason for lowering near-term expectations; that raises near-term analyst-model risk and may weigh on sentiment. Stifel Cuts MDT Target to $95
• Negative Sentiment: Competitive pressure in cardiac rhythm devices — Johnson & Johnson launched an enhanced pulsed-field ablation device in Europe, signaling faster product rollouts from competitors in electrophysiology that could pressure share gains in select cardiac franchises. J&J launches enhanced PFA device

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).